RCM Technologies (RCMT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
13 Nov, 2025Executive summary
Annual meeting scheduled for December 18, 2025, to be held virtually, with voting on key proposals including director elections, compensation, and auditor ratification.
Record date for voting is October 22, 2025, with 7,410,510 shares outstanding as of that date.
Board recommends voting for all proposals, including annual advisory votes on executive compensation.
Voting matters and shareholder proposals
Proposals include election of four directors, approval of the 2025 Omnibus Equity Compensation Plan, ratification of EisnerAmper LLP as independent accountants, advisory vote on executive compensation, and advisory vote on frequency of future compensation votes.
Board recommends annual advisory votes on executive compensation.
Shareholder proposals for the 2026 meeting must be received by July 16, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
Four director nominees: Bradley S. Vizi, Chigozie O. Amadi, Swarna Srinivas Kakodkar, and Jayanth S. Komarneni, each with significant industry and leadership experience.
Board committees (Audit, Compensation, Nominating & Corporate Governance) are composed entirely of independent directors.
Robust stock ownership guidelines and succession planning in place.
Code of Conduct and Code of Ethics adopted for all directors, officers, and employees.
Board leadership structure includes a Lead Independent Director.
Latest events from RCM Technologies
- Q2 profit and revenue rose, led by engineering and school healthcare, with strong liquidity.RCMT
Q2 20242 Feb 2026 - Healthcare and engineering drove Q3 gains, but net income and cash flow declined year-over-year.RCMT
Q3 202415 Jan 2026 - 2024 revenue rose 5.8% but profit fell; double-digit EBITDA growth targeted for 2025.RCMT
Q4 202424 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with focus on governance.RCMT
Proxy Filing2 Dec 2025 - Q1 2025 saw 17% revenue growth, higher earnings, and strong cash flow with share repurchases.RCMT
Q1 202525 Nov 2025 - Q2 2025 saw 13% revenue growth, record profit, and strong gains in key business segments.RCMT
Q2 202524 Nov 2025 - Q3 2025 revenue up 16.4% to $70.3M; record Engineering backlog and strong Healthcare momentum.RCMT
Q3 202513 Nov 2025